Results 211 to 220 of about 33,626 (284)

Opportunities and Limitations of Wrist-Worn Devices for Dyskinesia Detection in Parkinson's Disease. [PDF]

Sensors (Basel)
Wiederhold AJ, Zhu QR, Spiegel S, Dadkhah A, Pötter-Nerger M, Langebrake C, Ückert F, Gundler C.   +7 more
europepmc   +1 more source

Recurrent Belly Dancer’s Dyskinesia with Pregnancy

, 2019
Belal Aldabbour, Islam E’Leimat, Kefah Al‐Hayk, Aiman Momani   +3 more
openalex   +1 more source

Metabolic Stroke: Atypical Presentation of Succinic Semialdehyde Dehydrogenase Deficiency

JIMD Reports, Volume 67, Issue 2, March 2026.
ABSTRACT Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare autosomal recessive neurometabolic disorder caused by biallelic pathogenic variants in ALDH5A1, encoding the mitochondrial enzyme SSADH. This enzyme catalyses the conversion of succinic semialdehyde to succinic acid in the γ‐aminobutyric acid (GABA) degradation pathway.
Sharmila Kiss, Richard J. Leventer, Cormac Duff, Emma Macdonald‐Laurs, Olivia‐Paris Quinn, Fahaz Nazer, Michelle Cao, Abisha Srikumar, Jenzen Dalina, Mary Eggington, Joy Yaplito‐ Lee   +10 more
wiley   +1 more source

Exploring Ayurveda's Potential in Parkinson's Disease: A Comprehensive Narrative. [PDF]

Cureus
Chikkanna U, Venkatram S, Holla B, Mahale RR, Bhargav H, Jasti LN, Ramakrishna KK, Varambally S.   +7 more
europepmc   +1 more source

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments

, 2013
P Bargiotas, S Konitsiotis
openalex   +1 more source

SPHINCTER OCHSNER DYSKINESIA AS A CAUSE OF SUPERIOR MESENTERIC ARTERY SYNDROME

, 2016
Michael D Levin
openalex   +1 more source

Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 1, March 2026.
Abstract Background Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine‐induced acute parkinsonism.
Yasuhito Nagai, Miyata Mamiko, Koichi Miyakawa   +2 more
wiley   +1 more source

Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a <i>GBA1</i> Pathogenic Variant. [PDF]

Neurology
Avenali M, Artusi CA, Cilia R, Giannini G, Cuconato G, Albanese A, Golfrè Andreasi N, Antenucci P, Antonini A, Avanzino L, Baldelli L, Bentivoglio AR, Bove F, Bozzali M, Calandra-Buonaura G, Cani I, Carelli V, Cavallieri F, Cocco A, Cogiamanian F, Colucci F, Cortelli P, De Biase A, Di Biasio F, Di Fonzo A, D'Onofrio V, Eleopra R, Elia AE, Fioravanti V, Genovese D, Guerra A, Imarisio A, Ledda C, Liccari M, Longo C, Lopiano L, Malaguti MC, Malito R, Mameli F, Marino S, Minardi R, Mitrotti P, Monfrini E, Pacchetti C, Piano C, Rispoli V, Rizzone MG, Romito LM, Sambati L, Sensi M, Sorbera C, Spagnolo F, Tassorelli C, Valentino F, Valzania F, Zangaglia R, Zibetti M, Italian PARKNET Study Group, Valente EM.   +58 more
europepmc   +1 more source

Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study

Developmental Medicine &Child Neurology, Volume 68, Issue 3, Page 407-417, March 2026.
This original article is commented on by Kaufmann on pages 308–309 of this issue. Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.70051 Abstract Aim To describe the real‐world effects of trofinetide in individuals with Rett syndrome (RTT) using the 18‐month follow‐up analysis of the LOTUS study.
Louise Cosand, Haya Mayman, Jenny Downs, Victor Abler   +3 more
wiley   +1 more source